MarketCap
Facebook
X
Telegram
Accelerate Diagnostics Total Assets | AXDX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Accelerate Diagnostics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.6 M | 31.4 M | 65 M | 83 M | 93.4 M | 134 M | 185 M | 126 M | 82.9 M | 139 M | 69.8 M | 43.4 M | 17.2 M | 6.26 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 185 M | 6.26 M | 79 M |
Quarterly Total Assets Accelerate Diagnostics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.3 M | 22.9 M | 30.7 M | 31.4 M | 39.3 M | 49.9 M | 51 M | 65 M | 75.8 M | 58.7 M | 70.4 M | 83 M | 81.2 M | 94 M | 92.7 M | 93.4 M | 104 M | 115 M | 120 M | 134 M | 147 M | 159 M | 172 M | 185 M | 201 M | 218 M | 213 M | 126 M | 136 M | 148 M | 74.4 M | 82.9 M | 96.6 M | 111 M | 126 M | 139 M | 44.8 M | 53.3 M | 63.3 M | 69.8 M | 75.2 M | 81.8 M | 41.4 M | 43.4 M | 45.9 M | 29.3 M | 31.2 M | 13.3 M | 5.68 M | 6.01 M | 6.25 M | 6.11 M | 6.25 M | 6.26 M | 6.26 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 218 M | 5.68 M | 80.3 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 338.13 | 8.07 % | $ 16.8 B |  USA |
 |
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 30.33 | -0.57 % | $ 28.8 B |  Niderland |
 |
QIAGEN N.V.
QGEN
|
6.28 B | $ 50.36 | -0.98 % | $ 10.9 B | Niderland |
 |
RadNet
RDNT
|
3.76 B | $ 75.83 | -2.79 % | $ 5.7 B | USA |
 |
Senseonics Holdings
SENS
|
126 M | $ 8.58 | 7.38 % | $ 358 M | USA |
 |
T2 Biosystems
TTOO
|
34.8 M | - | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
142 M | $ 2.17 | -10.91 % | $ 143 M | USA |
 |
Thermo Fisher Scientific
TMO
|
110 B | $ 694.85 | 2.62 % | $ 262 B | USA |
 |
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Trinity Biotech plc
TRIB
|
103 M | $ 6.07 | 2.97 % | $ 2.18 B |  Irlanda |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 11.12 | 4.81 % | $ 378 M |  Israel |
 |
VolitionRx Limited
VNRX
|
6.9 M | $ 0.2 | 3.39 % | $ 25.2 M |  Singapore |
 |
Waters Corporation
WAT
|
5.08 B | $ 458.04 | 1.06 % | $ 27.3 B | USA |
 |
Exagen
XGN
|
58 M | $ 5.79 | -23.82 % | $ 125 M | USA |
 |
Guardant Health
GH
|
2.01 B | $ 151.28 | -1.4 % | $ 19 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 366.98 | 1.02 % | $ 30.5 B | USA |
 |
IQVIA Holdings
IQV
|
29.9 B | $ 271.72 | 2.59 % | $ 46.7 B | USA |
 |
Quotient Limited
QTNT
|
194 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
179 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
8.2 B | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
7.97 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
8.32 M | - | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
463 M | - | - | $ 1.49 B | USA |
 |
Celcuity
CELC
|
467 M | $ 66.73 | 3.9 % | $ 3.12 B | USA |
 |
DexCom
DXCM
|
6.34 B | $ 79.42 | -5.97 % | $ 31 B | USA |
 |
Agilent Technologies
A
|
12.7 B | $ 175.14 | 1.97 % | $ 49.7 B | USA |
 |
Castle Biosciences
CSTL
|
579 M | $ 32.49 | -4.99 % | $ 942 M | USA |
 |
Anixa Biosciences
ANIX
|
16.1 M | $ 3.16 | 4.29 % | $ 103 K | USA |
|
Biodesix
BDSX
|
87.5 M | $ 8.51 | -57.13 % | $ 64.3 M | USA |
 |
BioNano Genomics
BNGO
|
73.6 M | $ 1.15 | 4.54 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
684 M | $ 10.61 | -0.66 % | $ 707 M | USA |
 |
Fulgent Genetics
FLGT
|
1.21 B | $ 23.68 | 26.9 % | $ 729 M | USA |
 |
CareDx, Inc
CDNA
|
413 M | $ 78.47 | 2.8 % | $ 4.18 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M | Britain |
 |
Biomerica
BMRA
|
6.76 M | $ 1.61 | -1.55 % | $ 4.69 M | USA |
 |
Interpace Biosciences
IDXG
|
33.8 M | $ 7.0 | -13.43 % | $ 31 M | USA |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.3 B | $ 204.67 | 1.5 % | $ 16.1 B | Irlanda |
 |
Co-Diagnostics
CODX
|
24.7 M | $ 0.25 | -8.24 % | $ 333 K | USA |
 |
Burning Rock Biotech Limited
BNR
|
820 M | $ 13.2 | -0.38 % | $ 139 M |  China |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
DarioHealth Corp.
DRIO
|
110 M | $ 2.4 | -11.93 % | $ 9.56 M | Israel |
 |
Myriad Genetics
MYGN
|
707 M | $ 5.97 | -5.17 % | $ 553 M | USA |